Aaron Gerds, MD from Cleveland Clinics discusses Phase 2 Trial of Glasdegib in myelofibrosis was not launched – due to modest overall response in clinical activity at the 2017 American Society of Hematology.
Phase 2 Trial of Glasdegib in Myelofibrosis Was Not Launched – Due to modest overall response in clinical activity
By Editor